Lilly's halts trials of Zyprexa replacement in schizophrenia
This article was originally published in Scrip
Eli Lilly ceded defeat in its fight to replace some of the revenue lost to generic competition for its blockbuster Zyprexa (olanzapine) when on 29 August it announced it would end development of the schizophrenia drug candidate pomaglumetad methionil (LY2140023) – an oral glutamate 2 and 3 receptor agonist – after a second pivotal study failure.
You may also be interested in...
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?